There are currently 69 active clinical trials seeking participants for Type 1 Diabetes research studies. The states with the highest number of trials for Type 1 Diabetes participants are California, Texas, Florida and Colorado.
GO TEAM: Glucose Optimization Through Technology Assisted Management
NCT06074458
Recruiting
Black/African American children and young adults with type 1 diabetes are less likely to use diabetes technologies, such as continuous glucose monitors, insulin pumps, and automated insulin delivery systems, compared to White children and young adults. The investigators are working to find ways to make sure that all patients with type 1 diabetes are equally able to use these technologies. The purpose of this study is to find out if a new computer program for the diabetes team, along with a smart... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
07/23/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Type 1 Diabetes
Register for Updates
Effect of C-peptide on Hypoglycemic Counterregulation
NCT06470295
Recruiting
Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hy... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
01/07/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Hypoglycemia, Type 1 Diabetes
Register for Updates
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
NCT06832410
Recruiting
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/06/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania +3 locations
Conditions: Type 1 Diabetes, Kidney Transplant
Register for Updates
Registry for Stage 2 Type 1 Diabetes
NCT06481904
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: University of California San Francisco - Mission Bay- Site Number : 8400005, San Francisco, California +27 locations
Conditions: Type 1 Diabetes
Register for Updates
Denosumab for Type 1 Diabetes
NCT06524960
Recruiting
Type 1 diabetes (T1D) arises from abnormal immune cell-mediated injury to beta cells that make insulin. The injured beta cells can then no longer make the needed amount of insulin to stay healthy. However, in the early stages of T1D, some beta cells are still alive and functioning. Treatment to protect the beta cells against injury at this time could slow the progress of disease. Denosumab is an approved treatment for osteoporosis (a disease that thins and weakens the bones), high blood calcium... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/24/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +2 locations
Conditions: Type 1 Diabetes
Register for Updates
Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D
NCT06948760
Recruiting
A randomized controlled trial of Control-IQ, assessing glycemic control (time-in-range 70-180 mg/dL) for Lyumjev insulin (in which the insulin settings have been determined using an experimental conversion factor) as compared to Humalog or Novolog (using optimized settings)
Gender:
ALL
Ages:
Between 12 years and 22 years
Trial Updated:
07/24/2025
Locations: University of Virginia Center for Diabetes Technology, Charlottesville, Virginia
Conditions: Type 1 Diabetes
Register for Updates
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
NCT05414409
Recruiting
Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
07/22/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Type 1 Diabetes, Obesity
Register for Updates
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Kaiser Permanente Bonita Medical Offices, Bonita, California +80 locations
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Sansum Diabetes Research Institute, Goleta, California +147 locations
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
NCT06783309
Recruiting
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 208-day study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (90 days).
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
07/17/2025
Locations: Diablo Clinical Research, Walnut Creek, California +12 locations
Conditions: Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Register for Updates
Lipoprotein Kinetics in T1D
NCT05179954
Recruiting
The purpose of this research study is to understand how type 1 diabetes (T1D) increases the risk for cardiovascular diseases (heart attack and stroke). To this end, the investigators will compare apolipoprotein and triglyceride kinetics in people wtih T1D and healthy control participants.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/16/2025
Locations: University of Missouri School of Medicine, Columbia, Missouri
Conditions: Type 1 Diabetes
Register for Updates
Glu-COACH: a Peer-mentoring Intervention to Reduce Disparities in Continuous Glucose Monitor (CGM) Use
NCT06171412
Recruiting
This is a study to develop and evaluate a peer mentoring intervention for Black and Latinx adolescents with type 1 diabetes to increase the initiation and maintenance of a continuous glucose monitoring (CGM) device. This device is a standard of care to improve diabetes management related to diet, exercise, and insulin. Use of CGM has been shown to improve health outcomes, but is not used by adolescents of color. Peer mentors may help improve usage.
Gender:
ALL
Ages:
Between 13 years and 21 years
Trial Updated:
07/14/2025
Locations: Yale Children's Diabetes Clinic, New Haven, Connecticut
Conditions: Type 1 Diabetes
Register for Updates